Dr. Levitsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-8964- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1988 - 1991
- Johns Hopkins UniversityResidency, Internal Medicine, 1984 - 1987
- Johns Hopkins University School of MedicineClass of 1984
Certifications & Licensure
- MD State Medical License 1987 - 2022
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2002
Publications & Presentations
PubMed
- 70 citationsImaging CAR T cell therapy with PSMA-targeted positron emission tomography.Il Minn, David Jeffrey Huss, Hye Hyun Ahn, Tamara M. Chinn, Andrew Park, Jon Jones, Mary Brummet, Steven P. Rowe, Polina Sysa-Shah, Yong Du, Hyam I. Levitsky, Martin G...> ;Science Advances. 2019 Jul 1
- 130 citationsRapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Sabine Hoves, Chia Huey Ooi, Carsten Wolter, Hadassah Sade, Stefan Bissinger, Martina Schmittnaegel, Oliver Ast, Anna Maria Giusti, Katharina Wartha, Valeria Runza, We...> ;The Journal of Experimental Medicine. 2018 Mar 5
- 9 citationsParadoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.Deepak K. Kadayakkara, Michael J. Korrer, Jeff W.M. Bulte, Hyam I. Levitsky> ;Cancer Research. 2015 Jan 1
- Join now to see all
Press Mentions
- As Allogeneic Cell Therapy Approaches Flourish, Century Loads up $160M to Scale iPSC Platform for CAR-T, CAR-NKMarch 3rd, 2021
- Century Therapeutics Launches with USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy PlatformJuly 1st, 2019
- Bayer Powers Versant Cell Therapy Startup to $250M RoundJuly 1st, 2019
Grant Support
- Immunologic Targets In Myeloid LeukemiaNational Cancer Institute2010–2012
- Non-Invasive Quantification Of Vaccine-Mediated Antigen Delivery ToNational Cancer Institute2010–2011
- Regulatory T Cells In B Cell LymphomaNational Cancer Institute2008–2011
- Human ImmunologyNational Cancer Institute2006–2010
- Vaccination In Combination With Imatinib Mesylate For Chronic Myeloid LeukemiaNational Center For Research Resources2007
- K562/GM-CSF VaccinationNational Center For Research Resources2005–2006
- Cancer Vaccines In The Treatment Of CMLNational Cancer Institute2004–2005
- Immunotherapy For B Cell LymphomaNational Cancer Institute2002
- Tumor VaccinesNational Cancer Institute1997–2002
- Tumor Induced Antigen Specific T Cell ToleranceNational Cancer Institute1998–2000
- Vaccine Strategies To Enhance CD4+ T Cell PrimingNational Institute Of Allergy And Infectious Diseases1995–1998
- Novel T Cell Subset--Nk1+ Alpha BetaNational Cancer Institute1994–1995
- Strategies For Enhancing Antigen Specific ImmunityNational Institute Of Allergy And Infectious Diseases1994
- Analysis Of A Novel T Cell Subset--Nk1+ Alpha BetaNational Cancer Institute1991–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: